Dare Bioscience (DARE) Retained Earnings (2013 - 2026)
Dare Bioscience's (DARE) quarterly Retained Earnings came in at -$188.7 million in Q4 2025, down 7.64% YoY from -$204.3 million in Q4 2024, and down 0.77% on a QoQ basis from -$187.2 million in Q3 2025.
Dare Bioscience (DARE) Retained Earnings (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Retained Earnings data on file, last reported at -$188.7 million in Q4 2025.
- Quarterly Retained Earnings fell 7.64% year-over-year to -$188.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$188.7 million (down 7.64% YoY) and the FY2025 annual result came in at -$188.7 million, down 7.64% from the prior year.
- Retained Earnings fell to -$188.7 million in Q4 2025, from -$187.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$154973.0 in Q4 2021 to a low of -$188.7 million in Q4 2025.
- A 5-year average of -$96.3 million and a median of -$109.6 million in 2021 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 99.78% in 2021, down 77374.42% in 2021.
- Tracing DARE's Retained Earnings over 5 years: stood at -$154973.0 in 2021, then plunged by 126.69% to -$351311.0 in 2022, then sank by 48642.01% to -$171.2 million in 2023, then fell by 2.37% to -$175.3 million in 2024, then declined by 7.64% to -$188.7 million in 2025.
- The last three Retained Earnings figures came in at -$188.7 million (Q4 2025), -$187.2 million (Q3 2025), and -$183.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 4.38 Bn |
| 10 | Dare Bioscience | 12.21 Mn | -406,442.64 | -132,343.00 | -194.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -194.70 Mn |
| Dec 31, 2025 | -188.69 Mn |
| Sep 30, 2025 | -187.25 Mn |
| Jun 30, 2025 | -183.68 Mn |
| Mar 31, 2025 | -415,719.00 |
| Dec 31, 2024 | -175.29 Mn |
| Sep 30, 2024 | -169.80 Mn |
| Jun 30, 2024 | -385,560.00 |
| Mar 31, 2024 | -178.00 Mn |
| Dec 31, 2023 | -171.24 Mn |
| Sep 30, 2023 | -419,497.00 |
| Jun 30, 2023 | -157.90 Mn |
| Mar 31, 2023 | -373,316.00 |
| Dec 31, 2022 | -351,311.00 |
| Sep 30, 2022 | -125.13 Mn |
| Jun 30, 2022 | -299,992.00 |
| Mar 31, 2022 | -118.53 Mn |
| Dec 31, 2021 | -154,973.00 |
| Sep 30, 2021 | -100.60 Mn |
| Jun 30, 2021 | -87.92 Mn |